PIN53 Cost-Effectiveness Analysis of Pegylated Interferon Alpha-2A Versus Pegylated Interferon Alpha-2B in the Treatment of Chronic Hepatitis C Patients in Poland  by Macioch, T. et al.
PIN48
COST-EFFECTIVENESS OF A PENTAVALENT HUMAN-BOVINE REASSORTANT
ROTAVIRUS VACCINE (RV5) IN JAPAN
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OBJECTIVES: This study assesses the cost-effectiveness of universal vaccination
with RV5 in a hypothetical cohort of 1,091,156 children in Japan during their first 5
years of life. METHODS: A Markov model was developed to evaluate the cost per
quality-adjusted-life-year (QALY) from the healthcare and societal perspectives.
The base case scenario assumes 94% of the vaccinated cohort received 3 doses of
RV5 orally at 2, 4, and 6 months of age with the remaining children receiving only
1 or 2 doses. In the absence of a vaccination strategy, there is annually 1 death,
78,000 hospitalizations, and 739,874 outpatient visits. The efficacy of RV5 was
based on the results of the Rotavirus Efficacy and Safety Trial (REST). The three dose
efficacy in REST was similar to the one obtained from clinical trials conducted in
Japan. RESULTS: Universal vaccination could reduce hospitalizations by 89% and
all symptomatic episodes of rotavirus gastroenteritis by 59%. For the base case
scenario, at a cost of JPY 5316 per dose and administration fee of JPY ,100 per dose,
the cost per case avoided was JPY 22,704 and the cost per QALY saved was JPY
2,230,978 from the healthcare payer perspective. From the societal perspective, the
cost per case avoided was JPY 8,934 and the cost per QALY saved was JPY 877,855.
CONCLUSIONS: Using three times the GDP per capita as a threshold, universal
vaccination with RV5 is likely to be cost-effective and to result in substantial re-
ductions in rotavirus-related healthcare use in Japan.
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COST-EFFEECTIVENESS OF EARLIER INITIATION OF FIRST LINE COMBINATION
ANTIRETROVIRAL THERAPY IN AN URBAN OUTPATIENT HIV CLINIC IN
UGANDA
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Auerbach B, Sowinski S, Ssewankambo F, Manabe YC
Infectious Diseases Institute, Kampala, Uganda
OBJECTIVES:According to national guidelines, HIV-positive patients in Uganda are
to be initiated on combination antiretroviral therapy (cART) at a CD4 T-cell (CD4)
count below 250 cells/l. However, cART initiation at higher CD4 counts increases
survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-
effectiveness of initiating cART at CD4 counts between 250 – 349 cells/l vs. current
guidelines. METHODS: The average CD4 decline in untreated patients with CD4
counts below 550 cells/l occurs at a rate of 96.6 cells/l annually. Life expectancy
of cART-treated patients, conditional on baseline CD4 count, is modeled based on
published literature. First line cART costs US$192 annually, with an additional
US$113 per year for patient monitoring. Delay of cART until the CD4 count falls
below 250 cells/l incurs the cost of the bi-annual CD4 test and cost of routine
maintenance care at US$85 annually. The analysis compares lifetime treatment
costs and disability adjusted life-expectancy between early vs. delayed cART for
ten baseline CD4 count ranges from 250-259 to 340-349 cells/l. All costs and ben-
efits are discounted at 3% annually. RESULTS: Treatment delay varies from 0.5 year
(CD4: 250-299) – 1 year (CD4: 300-349). Early cART initiation increases life expec-
tancy between 1.48 and 3.01 years and averts 1.31 – 2.67 disability adjusted life
years (DALY’s) per patient. Lifetime treatment costs are US$4255 – US$5210 for
early initiation and US$3755 – US$4307 for delayed initiation. The cost/DALY
averted of the early versus delayed start ranges from US$354 – US$362.
CONCLUSIONS: In HIV-positive patients presenting with CD4 counts between 250-
350 cells/l, immediate initiation of cART is a highly cost-effective strategy using
the recommended 1 time per capita GDP threshold of $460 reported for Uganda.
Expanding the number of treatment slots to include patients with higher CD4
counts would constitute an efficient use of scarce health care dollars.
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THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF BOCEPREVIR IN
COMBINATION WITH PEGYLATED INTERFERON- ALFA AND RIBAVIRIN FOR
THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: A WITHIN
TRIAL ANALYSIS FROM THE PERSPECTIVE OF THE SCOTTISH NATIONAL
HEALTH SERVICE (NHS)
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OBJECTIVES: Chronic infection with the hepatitis C virus (HCV), if not cleared, can
cause severe liver damage and eventual death. Despite treatment with current
standard of care (pegylated interferon-alfa and ribavirin (PR)), sustained virologic
response (SVR) is achieved in less than half of genotype 1 HCV patients. This anal-
ysis evaluated the cost-effectiveness of boceprevir in combination with PR in treat-
ment-naïve and previously treated genotype 1 HCV patients, based on results of the
phase III clinical trials, and from the perspective of NHS Scotland. METHODS: A
Markov model was created to simulate the three treatment strategies studied in
the boceprevir phase III trials: boceprevir response guided therapy (RGT), where a
shortened treatment duration was possible for early responders; a full duration
boceprevir arm (4 weeks PR plus 44 weeks triple therapy); and a 48 week PR stan-
dard of care arm. Each treatment regimen including boceprevir was compared to
the PR standard of care arm. The incremental cost-effectiveness ratio (ICER) was
measured in terms of cost per quality adjusted life year. The efficacy values applied
were taken from the boceprevir clinical trials. In treatment naïve patients, 63% and
66% patients achieved SVR in the boceprevir RGT and full duration arms respec-
tively, compared to 38% in the control arm. In previously treated patients, 59% and
67% patients achieved SVR in the boceprevir RGT and full duration arms respec-
tively, compared to 21% who received PR alone. RESULTS: The ICER over current
standard of care lies between £6,462 and £13,299 for treatment naïve patients and
between £5,248 and £6,684 for treatment experienced patients, depending on treat-
ment duration. CONCLUSIONS: The addition of boceprevir to current standard of
care for HCV genotype 1 patients is clinically efficacious and cost-effective, and
comfortably below a threshold of £20,000 per QALY, irrespective of whether pa-
tients have been previously treated.
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A COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN FOR
VENTILATOR-ASSOCIATED PNEUMONIA PATIENTS IN PANAMA
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OBJECTIVES:Ventilator-associated pneumonia (VAP) is the most common nosoco-
mial infection in the intensive care unit (ICU). It’s associated with significant mor-
bidity, increasing the ICU and hospital length of stay (LOS), and raising overall
costs. Panama=s statistics are similar to those reported in developed countries.
Literature suggests that costs could be reduced using the most efficient empiric
therapy. The aim of this study was to assess the cost-effectiveness (CE) of linezolid
against generic vancomycin as an empiric therapy for VAP patients, from the
health care payer’s perspective. METHODS: A decision-tree model was used to
compare costs and effectiveness of linezolid (600mg/12 hours) and vancomycin (1g/
12 hours) (comparator) for a cohort of patients with VAP. Effectiveness measures
were: clinical and microbiological success rates, mortality rates, ICU LOS and over-
all costs. Effectiveness and epidemiologic data were collected from published lit-
erature. Local costs (2011 US$) were obtained from Panama=s Social Security official
databases. The model used a 12-week time horizon and only direct medical costs
were considered (hospital LOS, medication costs, hematologic, gastrointestinal
and skin adverse events and lab exams). Monte Carlo probabilistic sensitivity anal-
ysis (PSA) was constructed. RESULTS: Results showed linezolid as more effective
and less expensive option for VAP. Clinical success rate was higher with linezolid
(64%) against vancomicyn, (59.5%). Mortality was lower with linezolid (10.13% vs.
15.74%). Average ICU LOSs was 17.4 days with linezolid and 21.26 days with van-
comycin. Overall medical costs per patient were $19,507 with linezolid and $20,411
with vancomycin. CE analyses showed linezolid is the dominant strategy. Accept-
ability curves showed that linezolid would be cost-effective within 3 GDP per
capita threshold. PSA outcomes support the robustness of these findings.
CONCLUSIONS: This is the first CE study for VAP developed in Panamá. Linezolid
resulted as the cost-saving option for treating VAP patients in the Panamanian
clinical environment.
PIN52
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TUBERCULOSIS TREATMENT IN UGANDA
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OBJECTIVES: Approximately 40,000 new TB cases are treated annually in Uganda,
and 4,000 are reported to require re-treatment (category II treatment). Current
tuberculosis (TB) treatment in Uganda is standard 4 drug therapy in intensive
phase (2 months), followed by isoniazid and ethambutol for 6 months (6HE). How-
ever, the World Heath Organization recommends isoniazid and rifampicin for 4
months (4HR) in the continuation phase, which is associated with better efficacy.
We sought to investigate the cost-effectiveness of 4HR vs. 6HE. METHODS: Ran-
domized clinical trial evidence indicates a significant decrease in the rate of treat-
ment failure and relapse associated with 6HE versus 4HR from 10.0% to 5.0%. The
median international daily drug price is HR: US$0.115 and HE: US$0.069. When the
initial regimen is not successful, re-treatment is associated with a mortality rate of
up to 23% and involves an additional 8 month drug-regimen at a cost of US$39.25.
A decision tree was used to calculate the expected total cost of TB treatment in the
4HR versus 6HE arm. RESULTS: The cost of TB treatment in the continuation phase
is 4HR: US$13.82 and 6HE: US$12.46. However, once the cost of re-treatment is
factored in, the average weighted treatment cost is 4HR: US$15.79 and 6HE:
US$16.38. Replacing 6HE with 4HR nationally could decrease the annual cost of TB
treatment by an estimated US$23,500 and prevent about 2,000 TB treatment fail-
ures and relapses per year. CONCLUSIONS: Combination therapy with 4HR in the
continuation phase dominates 6HE, as it is associated with improved effectiveness
and a lower average cost per patient. Since treatment failure or relapse is associ-
ated with worsened clinical outcomes in resource constrained settings, consider-
able gains to population health could be achieved at lower cost if 4HR became the
new standard of care in the continuation phase of TB treatment in Uganda.
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COST-EFFECTIVENESS ANALYSIS OF PEGYLATED INTERFERON ALPHA-2A
VERSUS PEGYLATED INTERFERON ALPHA-2B IN THE TREATMENT OF CHRONIC
HEPATITIS C PATIENTS IN POLAND
Macioch T1, Paweska J1, Niewada M1, Berak H2, Szkultecka-Debek M3,
Russel-Szymczyk M3
1HealthQuest Sp.z o.o., Warsaw, Poland, 2Hospital for Infectious Diseases, Warsaw, Poland,
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OBJECTIVES: To assess cost-effectiveness of pegylated interferon alpha-2a
(PegIFN2a) vs. pegylated interferon alpha-2b (PegIFN2b) in the treatment of
chronic hepatitis C (HCV) patients from Polish public payer perspective.METHODS:
Systematic review assessed clinical efficacy and safety of the two treatment op-
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tions. Seven state Markov model (chronic HCV, sustained virological response,
compensated cirrhosis, hepatocellulare carcinoma, liver transplantation and
death) was used to estimate clinical effects and costs in lifetime horizon, from
Polish public payer perspective. Direct medical costs were considered. Separate
analysis was done for genotypes 1,4 (48-week treatment) and genotypes 2,3 (24-
week treatment). Clinical practice and cost data were gathered from clinical ex-
perts or based on the National Health Fund and Ministry of Health published price
lists. Sensitivity analysis was conducted in order to assess the robustness of the
results. RESULTS: Genotypes 1 and 4: total costs were 92 036 PLN (1 Euro3.96 PLN)
for PegIFN2a and 87 793 PLN for PegIFN2b. Average survival of HCV patient
treated with PegIFN2a was 27.9 life years (LY) and 14.83 quality adjusted life years
(QALY) and treated with PegIFN2b was 27.63 LYs and 14.61 QALYs. The incremen-
tal cost-effectiveness ratio was 15 878 PLN/LYG and incremental cost-utility ratio
was 19 763 PLN/QALY. Values of both ratios fall below the cost-effectiveness
threshold assumed in Poland (100 000 PLN/LYG or QALY). Genotypes 2 and 3: Total
costs were 32 849 PLN for PegIFN2a and 38 071 PLN for PegIFN2b. Average survival
of HCV patient treated with PegIFN2a was 30.79 LYs and 17.15 QALYs and treated
with PegIFN2b was 30.20 LYs and 16.68 QALYs. The PegIFN2a dominated
PegIFN2b. The results were confirmed in sensitivity analysis. CONCLUSIONS:
PegIFN2a is a clinically effective and safe treatment for HCV patients and is highly
cost-effective (or dominant) from Polish public payer perspective.
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COST-EFFECTIVENESS OF 21 DOSING OF 13-VALENT PNEUMOCOCCAL
CONJUGATE VACCINE COMPARED WITH 21 DOSING OF 10-VALENT
CONJUGATE VACCINE IN PREVENTING PNEUMOCOCCAL DISEASE IN CANADA
Earnshaw S1, Mcdade C1, Zanotti G2, Farkouh RA3, Strutton D4
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OBJECTIVES: Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-
valent pneumococcal conjugate vaccine (PCV10) are two approved vaccines for the
active immunization against Streptococcus pneumoniae, causing invasive pneumo-
coccal disease in infants and children. PCV13 offers broader protection against
Streptococcus pneumoniae; however, PCV10 offers potential additional protection
against non-typeable Haemophilus influenzae. We examined public health and eco-
nomic impacts of a PCV10 and PCV13 pediatric national immunization programs
(NIPs) in Canada.METHODS: A decision-analytic model was developed to examine
the costs and outcomes associated with a 21 dosing of PCV10 and 21 dosing of
PCV13 pediatric NIP. The model followed patients over the remainder of their life-
time. Recent disease incidence, serotype coverage, population data, percent vacci-
nated, costs, and utilities were obtained from the published literature. Direct and
indirect effects were derived from 7-valent pneumococcal vaccine. Additional di-
rect effect of 4% was attributed to PCV10 for moderate to severe AOM to account for
potential non-typeable Haemophilus influenzae benefit. Annual number of disease
cases and costs (2010 CAN$) were presented. RESULTS: In Canada, PCV13 pre-
vented more cases of disease (7,465 when considering direct effects only and 49,340
when considering both direct and indirect effects) than PCV10. This translated to
population gains of 80,565 to 94,134 more quality-adjusted life years when vacci-
nating with PCV13 versus PCV10. Use of PCV13 in children also reduced annual
direct medical costs (including the cost of vaccination) by $5.8 to $132.8 million.
Thus, PCV13 was found to dominate PCV10. One-way sensitivity analyses showed
PCV13 to always be dominant or cost-effective versus PCV10. CONCLUSIONS: Con-
sidering the epidemiology of pneumococcal disease in Canada, 21 dosing of
PCV13 is shown to be a cost saving immunization program as it provides substan-
tial public health and economic benefits relative to 21 dosing of PCV10.
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OBJECTIVES: The analysis aimed to evaluate the cost-effectiveness of 48-week
therapy with peginterferon alpha-2a (PegIFN-2a) in HBeAg-positive chronic hep-
atitis B (CHB) patients versus 48-week (short-term analysis) or 4-year (long-term
analysis) therapy with adefovir, entecavir or lamivudine from the public payer
perspective in Poland. METHODS: A life-time Markov model based on previously
published analysis was used. States encompassed treatment response (HBeAg se-
roconversion), relapse, complications (compensated/decompensated cirrhosis,
hepatocellular carcinoma, liver transplantation) and death. Quality-adjusted life
years (QALYs) were the measure of effectiveness. Short-term efficacy assessment
was based on the results of randomized clinical trials (RCTs). Long-term efficacy
data for nucleos(t)ide analogues (NAs) were derived from published models and
RCTs extensions. Utilities and transition probabilities (spontaneous response, re-
lapse, complications, death) were taken from published literature. Direct medical
costs, i.e. costs of drugs and procedures used in the treatment of CHB and its
complications were obtained using a survey conducted among Polish clinicians. In
the base case analysis costs and benefits were discounted at a 5% and 3.5% annual
rate, respectively. The robustness of the results was assessed using one-way, sce-
nario and probabilistic sensitivity analyses. RESULTS: In both the short and long-
term analysis PegIFN-2a increased number of QALYs and life years gained (LYGs)
compared to all investigated NAs. In the short-term model PegIFN-2a decreased
the costs of complications’ treatment and increased the overall costs due to drug
acquisition cost. ICER for PegIFN-2a vs. lamivudine, adefovir and entecavir
amounted to 50,809, 11,442 and 39,588 PLN/QALY, respectively (1€4 PLN). In the
long-term model costs of NAs were higher. PegIFN-2a was cost-saving and dom-
inated adefovir and entecavir, while ICER versus lamivudine amounted to 27,431
PLN/QALY. Sensitivity analysis proved these results to be robust. CONCLUSIONS:
Peginterferon alfa-2a is cost-effective when compared to adefovir, entecavir and
lamivudine in Poland.
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COST-EFFECTIVENESS MODEL TO EVALUATE 200-DAY VS 100-DAY
TREATMENT WITH VALGANCICLOVIR PROPHYLAXIS TO REDUCE
CYTOMEGALOVIRUS DISEASE IN HIGH-RISK (D/R-) KIDNEY TRANSPLANT
RECIPIENT IN SPAIN
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OBJECTIVES: IMPACT trial showed that prolonged prophylaxis of 200 days with
valganciclovir (VGC 200) compared with 100 days (VGC 100) significantly decreases
the incidence of cytomegalovirus (CMV) disease. Therefore, a cost-effectiveness
model was developed to evaluate prolonged prophylaxis of 200 days with valgan-
ciclovir and its long term economic impact . METHODS: A Markov model was
designed to simulate the CMV disease progression; costs and outcomes associated
with the use of VGC 200 vs VGC 100 in a cohort of 10,000 patients over 10 years was
examined. Data of the disease evolution were obtained from the IMPACT (Humar,
Am J Transplant 2010) for year 1 and the available scientific evidence for years 2-10.
The analysis was conducted from the perspective of the Spanish National Health-
care System (SNHS), considering direct medical costs. Unitary costs (€, 2010) were
obtained from a Spanish database. Utility values were obtained from literature. The
annual discount rate was 3% for costs and outcomes. RESULTS: Treatment with
VGC 200 provides better results in health than VGC 100 (50,020.30 vs. 47,639.90
QALY/patient). The average overall cost per patient is €1,121,327 with VGC 200 and
€1,131,187 with VGC 100. The savings per patient treated with VGC 200 in 10 years
is €986. Sensitivity analysis confirms the stability of the results. CONCLUSIONS:
Treatment of patients with prolonged prophylaxis valganciclovir reduces the inci-
dence in high risk kidney transplant recipients and is a cost-saving strategy in CMV
disease management from the perspective of the SNHS.
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COST-EFFECTIVENESS OF THE NEW GUIDELINES FOR THE PREVENTION OF
MOTHER TO CHILD TRANSMISSION OF HIV IN UGANDA
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Infectious Diseases Institute, Kampala, Uganda
OBJECTIVES: In Uganda, 91,000 children are born annually to HIV-positive moth-
ers, approximately 25,000 of which become HIV-infected. New guidelines recom-
mend the use of combination antiretroviral therapy (cART) to prevent vertical
transmission. We evaluate the cost-effectiveness of more costly cART relative to
other or no preventative therapies. METHODS: Currently, about 48.4% of HIV-pos-
itive pregnant women do not receive any preventive therapies and therefore have
a 40% risk of transmitting HIV to their child during pregnancy or breastfeeding.
This risk can be reduced to 25.8% by single dose nevirapine (sdNVP; Cost: US$0.06),
to 17.4% by dual therapy (3TC/AZT; Cost: US$16 for 7 weeks) and to 3.8% by cART
(Cost: US$470 for 18 months). At CD4 counts below 350 cells/l, lifetime cART is
indicated for the mother (Cost: US$ 6,883), which reduces future transmission risk
in an additional 3.49 pregnancies. The model calculates disability adjusted life
years (DALY’s) between therapies based on differences in HIV-transmission to chil-
dren, which results in shortened life-expectancy. All costs and benefits are dis-
counted at 3% annually. RESULTS: Replacing sdNVP and 3TC/AZT with cART could
reduce annual HIV transmissions by 7,500 cases. Preventing one infection averts
23.7 DALY’s. Hence, DALY’s averted using 18 months cART versus sdNVP, 3TC/AZT,
and no therapies are 5.21, 3.22, and 8.58, and yield a cost/DALY averted of US$46,
US$99, and US$34, respectively. The corresponding figures for lifetime cART are
19.20, 11.87, and 31.60, resulting in a cost/DALY averted of US$205, US$354 and
US$172, respectively. CONCLUSIONS: Using the 1 time per capita GDP threshold
(US$460), cART as proposed in the new Ugandan guidelines is highly cost-effective
relative to other drugs and would generate additional value if treatment could
reach greater numbers of women. It remains highly cost-effective even if treatment
is continued over the patients’ lifetimes. It is imperative that these guidelines are
rapidly implemented.
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COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL 13-VALENTE
CONJUGATE VACCINE VERSUS PNEUMOCOCCAL 10-VALENTE CONJUGATE
VACCINE IN THE PEDIATRIC IMMUNIZATION ROUTINE, FROM THE SÃO PAULO
STATE PUBLIC HEALTH CARE SYSTEM (BRAZIL)
Pepe C1, Teich V1, Mould JF2
1MedInsight, São Paulo, São Paulo, Brazil, 2Pfizer, Inc., New York, NY, USA
OBJECTIVES: It is estimated that pneumococcal disease is responsible for more
than a million deaths per year in children less than five years of age worldwide.
This study aim to perform a cost-effectiveness analysis comparing pneumococcal
13-valent conjugate vaccine (PCV13) against pneumococcal 10-valent conjugate
vaccine in prevention of invasive pneumococcal diseases (IPD), acute otitis media
(AOM) and pneumonia, from the São Paulo Public Healthcare System perspective.
METHODS: The type of study was cost-effectiveness analysis based on a decision
tree model to estimate costs and consequences of prophylaxis. Epidemiological
and efficacy data was collected from a critical appraisal of the scientific literature,
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